[ad_1]
On July 20, Biogen Inc. agreed to pay $900 million to settle claims the company violated the False Claims Act by allegedly paying improper consulting and speaker fees and providing lavish meals and entertainment to medical providers to induce them to prescribe the multiple sclerosis drugs it manufactures.
Read on for details about this unusually large settlement, which highlights the risks associated with pharmaceutical and device manufacturers hiring providers as consultants and conducting speaker programs.
[ad_2]
Source link
